The National Pediatric Cancer Foundation has awarded a $1 million research grant to a scientist at Children’s Hospital Los Angeles to tackle one of the most lethal childhood cancers, a rare sarcoma that almost always returns after initial treatment. The funding aims to unlock why the disease resists chemotherapy and to develop therapies that could finally improve survival rates that have not budged in years.
The cancer, known as Metastatic Fusion-positive Rhabdomyosarcoma (MFPRMS), is driven by a specific genetic abnormality called the PAX3-FOXO1 fusion oncoprotein. While the tumor often responds dramatically to initial therapy, with scans showing complete disappearance of disease, it nearly always comes back. The 3-year event-free survival rate stands at only about 10 percent, and no new drugs are ready for testing in early-stage clinical trials. The disease is so rare that studying it is extremely difficult, especially because it primarily affects children, a vulnerable group for research. The foundation notes that only about 4 percent of federal cancer research funding goes to childhood cancers, creating a critical gap this grant is designed to help close.
The grant was awarded to Dr. JinSeok Park, who has discovered a surprising mechanism driving the cancer’s aggression and resistance. His research shows that MFPRMS tumors form groups of cells with two distinct roles. On the outer edge are “leader cells” that have lower levels of the abnormal PAX3-FOXO1 gene. These cells are the first to invade surrounding tissue, creating space for the tumor to grow. Inside the core are “follower cells” with higher PAX3-FOXO1 expression, which multiply rapidly to fill that space and push the leader cells outward, driving explosive tumor growth. Crucially, when PAX3-FOXO1 levels are reduced, cancer cells slow their multiplication, which may explain why they resist drugs designed to target fast-growing cells.
Dr. Park’s team believes these marginal leader cells act as a shield, protecting the tumor mass from chemotherapy and contributing to inevitable recurrence. The research will investigate how the tumor reduces PAX3-FOXO1 expression at its edges and how this process promotes drug resistance. By understanding this shielding mechanism, Dr. Park aims to identify new therapeutic strategies to overcome resistance and improve outcomes for children battling this devastating cancer. The foundation hopes this investment will accelerate progress for children facing the most difficult-to-treat cancers and inspire further discoveries that have been waiting for funding.